Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Multiple Sclerosis
Clinical trial register · United States · industry-sponsored

Multiple Sclerosis Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9159 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 24 Oct 2026, 03:16 UTC
9159
Studies in scope
industry-sponsored, all four open statuses
4969
Recruiting now
open to new participants
2198
Lead sponsors
across recruiting studies
Top states
California 21 Florida 13 Colorado 13 Arizona 12 Massachusetts 11
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hoffmann-La Roche7 Novartis Pharmaceuticals6 Sanofi4 Biogen4 Bristol-Myers Squibb3
State
California21 Florida13 Colorado13 Arizona12 Massachusetts11
All 29 states
Target enrolment
to

Multiple Sclerosis trials in the USA

42 of 9159 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
NCT07825389Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS)
DrugC-CAR168
AbelZeta Inc.
Phase 1/2
119
Arizona, California
2027-02
Recruiting
Genentech, Inc.
Phase 4
100
Arizona, Florida, Georgia, Tennessee
2026-09-02
Recruiting
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia
NCT07732907Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy
DrugOzanimod
Bristol-Myers Squibb
Observational
15
New Jersey
2026-06-04
Recruiting
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
NCT07304154Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis
DrugsKITE-363·Fludarabine·Cyclophosphamide
Kite, A Gilead Company
Phase 1
57
California, New York, Utah, Washington
2026-04-10
Recruiting
Novartis Pharmaceuticals
Observational
7,466
New Jersey
2026-04-08
Active, closed
Novartis Pharmaceuticals
Observational
2,607
New Jersey
2026-03-06
Recruiting
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT07477639Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive
DrugBendamustine
Tr1X, Inc.
Phase 1/2
39
California, Kansas, Minnesota, Missouri, New York, North Carolina, Ohio, Washington
2026-03-01
Recruiting
Sanofi
Phase 3
160
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland
2026-01-14
Recruiting
AstraZeneca
Phase 1
24
Arizona, Colorado, District of Columbia, Missouri, New York, Ohio, Washington, Wisconsin
2025-12-09
Active, closed
Hoffmann-La Roche
Phase 2
193
California, Colorado, Florida, Maryland, Massachusetts, New York, Tennessee, Washington
2025-11-13
By invitation
Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)
NCT07221565Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases
DrugNaltrexone
Truway Health, Inc.
Phase 1/2
120
New York
2025-10-23
Active, closed
Genentech, Inc.
Phase 1
60
California, Missouri, New Jersey, New York
2025-10-15
Active, closed
"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"
NCT06800404Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis
DrugAutologous HB-adMSCs
Hope Biosciences Research Foundation
Phase 2
10
Texas
2025-05-02
Recruiting
ModernaTX, Inc.
Phase 2
180
Massachusetts, Michigan, Missouri, Oklahoma, Texas
2025-04-16
Active, closed
Hoffmann-La Roche
Phase 1
75
California, Florida, Georgia, Maryland, Tennessee
2024-12-17
Active, closed
Novartis Pharmaceuticals
Phase 4
24
California, Colorado, Illinois, Massachusetts
2024-11-25
Active, closed
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
NCT06384976Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, MS
DrugKYV-101
Kyverna Therapeutics
Phase 2
120
California
2024-09-20
Recruiting
TG Therapeutics, Inc.
Observational
2,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-07-22
Active, closed
Biogen
Observational
10,500
Massachusetts
2024-06-08
Recruiting
TG Therapeutics, Inc.
Observational
728
North Carolina
2024-06-01
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
120
Alabama, California, Colorado, Connecticut, Kansas, Massachusetts, Missouri, New Jersey
2024-03-28
Active, closed
Sanofi
Phase 3
943
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-12-27
Active, closed
Sanofi
Phase 3
1,655
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-12-13
Recruiting
Biogen
Observational
908
Colorado, North Carolina
2023-10-27
Recruiting
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
NCT05964829Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
Cionic, Inc.
Not applicable
14
Ohio
2023-09-04
Active, closed
Celestra Health Systems
Observational
90
Massachusetts
2023-07-01
Active, closed
Biogen
Observational
400
Massachusetts
2023-06-30
Active, closed
Helius Medical Inc
Observational
150
Pennsylvania
2023-05-01
Recruiting
Kesimpta (Ofatumumab) Pregnancy Registry
NCT05634967Multiple Sclerosis, Pregnancy
Novartis Pharmaceuticals
Observational
725
California
2023-01-05
Recruiting
Bristol-Myers Squibb
Observational
1,182
Maryland
2022-07-15
Active, closed
Hoffmann-La Roche
Phase 3
1,300
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Kansas
2022-05-03
Recruiting
Novartis Pharmaceuticals
Observational
867
California
2021-12-15
Active, closed
Immunic AG
Phase 3
1,121
Arizona, California, Florida, Illinois
2021-11-18
Active, closed
Biogen
Observational
1,178
Minnesota
2021-09-24
Active, closed
ImStem Biotechnology
Phase 1
30
Georgia, Massachusetts, Utah
2021-08-31
Active, closed
Hoffmann-La Roche
Phase 1
119
California, Connecticut
2021-08-11
Active, closed
Sanofi
Phase 2
129
Arizona, Florida, North Carolina, Wisconsin
2021-06-07
Active, closed
Bristol-Myers Squibb
Observational
2,961
Minnesota
2021-03-16
Active, closed
Hoffmann-La Roche
Phase 3
769
Alabama, Arizona, California, Colorado, Florida, Kentucky, Maryland, Massachusetts
2020-12-03
Active, closed
Hoffmann-La Roche
Phase 3
864
Alabama, Arizona, California, Colorado, Florida, Indiana, Kansas, Louisiana
2020-11-26
Active, closed
Hoffmann-La Roche
Phase 2
23
Colorado, District of Columbia, Massachusetts, Missouri, Ohio
2020-01-09
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Alabama, California, Florida, Massachusetts, Michigan, New Jersey, Pennsylvania, Utah
2013-07-26
Rows per page Showing 1–42 of 42
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/multiple-sclerosis

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,159 studies in total at the last sync on 24 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 42 of those studies listing the condition Multiple Sclerosis.

How many Multiple Sclerosis trials are recruiting in the US?

15 of the 42 studies on this page are recruiting new participants as of the 24 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 25 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Multiple Sclerosis), 42 studies
PhaseStudiesRecruitingShare
Observational15835.7%
Phase 38119%
Phase 17216.7%
Phase 26114.3%
Phase 1/2317.1%
Phase 4214.8%
Not applicable112.4%

Most active sponsors

Lead sponsors with the most studies (Multiple Sclerosis)
Lead sponsorStudiesRecruiting
Hoffmann-La Roche70
Novartis Pharmaceuticals63
Biogen41
Sanofi41
Bristol-Myers Squibb32
Genentech, Inc.21
TG Therapeutics, Inc.22
AbelZeta Inc.10
AstraZeneca11
Celestra Health Systems10

Top states

Top states (Multiple Sclerosis), by number of studies with a site there
StateStudies
California21
Colorado13
Florida13
Arizona12
Massachusetts11
Alabama8
Georgia8
Missouri6
New Jersey6
New York6
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.